IPO Details - Medline had the largest IPO in over four years, offering $626 billion [1] - The IPO was unexpected, as Medline is not a widely recognized name [1] Business Model & Strategy - Medline's revenue is evenly split between its own brand medical surgical products and supply chain solutions [2] - Earnings are primarily derived from product sales [2] - The supply chain business provides insights into hospital needs and facilitates product distribution [2] - Medline aims to be the "Costco of healthcare" [3] - It employs a membership model through its supply chain business to offer healthcare providers the best prices [3] - Medline brand products are positioned similarly to Costco's Kirkland signature brand [3] Revenue Growth - Medline experienced solid revenue growth in recent years: 83% in 2023, 98% in 2024, and 103% through the first 9 months of 2025 [4] - Revenue growth appears to be accelerating [4]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Viewpoint - SRx Health (SRXH) has experienced a significant share price increase of 85% following its announcement to pivot into digital asset treasury management and merge with EMJ Crypto Technologies in a deal valued at approximately $55 million [1][2]. Group 1: Company Developments - The merger with EMJ Crypto Technologies is an all-stock deal valued at about $55 million, indicating a strategic shift for SRx Health towards digital assets [1]. - Eric Jackson, a notable hedge fund manager, will lead the combined company post-transaction, which is expected to close in the first quarter of 2026 [2]. Group 2: Market Reaction - Following the announcement, SRXH shares were trading over 200% higher than their year-to-date low in November, reflecting a strong initial market reaction [2]. - However, by the market close on December 16, SRXH stock reversed nearly all of its intraday gains, suggesting that the price surge was more sentiment-driven rather than fundamentally supported [3]. Group 3: Investment Considerations - The digital asset treasury strategy of SRx Health is considered speculative and untested, raising concerns about its viability as an investment [4]. - The broader cryptocurrency market is currently struggling, which may hinder the potential success of SRx Health's strategy in the near term [5]. - SRx Health shares are trading at less than $1, which poses a risk of delisting and exposes investors to price manipulation risks typical of penny stocks [6]. Group 4: Analyst Coverage - There is a notable absence of Wall Street coverage for SRx Health, meaning there are no analysts evaluating the company's claims or providing independent earnings models for benchmarking [7].

Joining us right now first on CNBC is Medline CEO Jim Bole. Good morning to you. >> Good morning.>> Congratulations. This been this has been a quite a road for you to get to to this point. Uh why go public now.What's the what's what's the thinking in terms of where you came from and where you are right now. >> And as you know, we've been a private company for 58 years. Um with 58 years of consecutive growth, uh we just feel like this is the right time for us to kind of expand our voice.Historically, we've d ...

Core Viewpoint - Investors are advised to consider dividend ETFs as a defensive strategy during potential market downturns, with historical performance indicating resilience during recessions [1][2]. Group 1: Dividend ETFs Overview - The State Street Consumer Staples Select Sector SPDR ETF (XLP) focuses on companies selling essential goods, providing stability during economic downturns due to inelastic demand for consumer staples [3][4]. - The State Street Health Care Select Sector SPDR ETF (XLV) includes large healthcare companies, benefiting from consistent demand for medical services regardless of economic conditions [6][7]. - The iShares TIPS Bond ETF (TIP) offers exposure to U.S. Treasury Inflation-Protected Securities, serving as a hedge against inflation and providing liquidity [9][10]. Group 2: Performance and Characteristics - XLP has 40 holdings, with Walmart (11.64%), Costco (9.08%), and Procter & Gamble (7.67%) as its largest components, featuring a 2.66% dividend yield and a low expense ratio of 0.08% [5]. - XLV has outperformed the S&P 500 during past downturns, showing a 12% increase over the past year, with a 1.58% dividend yield and an expense ratio of 0.08% [8]. - TIP has a dividend yield of 3.29%, which fluctuates with inflation, and an expense ratio of 0.18% [10][11].

[applause] At some point in life, we all become the caregiver. And what I'm sharing with you today is based on lived experience, hard work, and science with only one goal to inspire you and maybe help you look differently at something we think we all understand. That is how we care for others.Today we are facing an epidemic of burnouts in health care, in classrooms, and even in friendships. But what if the key to a truly humane society lies in a common skill, one that could benefit us all. Because the probl ...

Group 1 - The employment environment for U.S. job seekers in 2025 is expected to be challenging, with a projected unemployment rate of 4.4% as of September, the highest since October 2021 [3][4] - Job growth is weak, with increasing layoffs and a stagnant hiring rate, particularly in the healthcare sector, which accounted for 47.5% of annual job growth as of August [3][4] - Experts predict a continuation of the "low hiring, low layoffs" trend, with concerns about a potential mild recession impacting vulnerable groups [4] Group 2 - Gold futures are currently trading around 978.88 yuan per gram, with a 1.48% increase, indicating a short-term bullish trend [1] - The gold market is in a consolidation phase, having broken above the 940-950 range, with support levels identified between 968-965 yuan and resistance levels at 975-980 yuan [5] - Recent price movements suggest a normal technical correction rather than a trend reversal, with the market expected to maintain an upward trajectory as long as key support levels hold [5]

Meet the movers and shakers across industries like art, sports, AI, social media, healthcare and more. #ForbesUnder30Read more: https://t.co/e8L3DT968G https://t.co/QEj0kS07oa ...

Heard on the Street: Companies like Cigna and CVS are promising simpler drug prices, but the behind-the-scenes system remains complex https://t.co/VwbvflQ366 ...

Core Viewpoint - GE HealthCare is positioned for growth in the healthcare technology sector, with a new price target set by Jefferies indicating a potential increase in stock value [1][6] Company Overview - GE HealthCare specializes in medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, competing with major players like Siemens Healthineers and Philips Healthcare [1] - The company's current stock price is $85.55, reflecting a slight increase of 1.28% [2] - Over the past year, the stock has experienced significant volatility, with a high of $94.80 and a low of $57.65, and a market capitalization of approximately $39.08 billion [2][6] Strategic Partnerships - GE HealthCare has expanded its collaboration with Imaging Biometrics Ltd, enhancing its neuroimaging capabilities with advanced tools like FTB Express maps and QSMetric [3][5] - The FTB Express tool integrates with existing workflows, providing faster access to critical data for clinicians [4] - This partnership underscores GE HealthCare's commitment to innovation and improving patient outcomes, potentially strengthening its market position [5]